New Parkinson's pill aims to cut 'OFF' time and ease daily struggles
NCT ID NCT07514858
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 2 trial tests whether adding Lu AF28996 to standard Parkinson's medications can extend the time patients feel their movement symptoms are well-controlled (called 'good ON time'). About 150 adults with Parkinson's who still experience motor fluctuations despite optimized treatment will receive either the drug or a placebo. The main goal is to see if the drug increases daily good ON time without troublesome dyskinesia over 19 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Lu AF28996
What this could lead to
If successful, this could provide a new add-on medication to help Parkinson's patients spend more time with well-controlled movement symptoms and less time in 'OFF' periods.
What could go wrong
This is an early Phase 2 trial with only 150 participants, so results may not confirm benefit. The drug may cause side effects or fail to outperform placebo.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PARKINSON'S DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••